Login to Your Account



Lilly breast cancer drug hits phase III endpoint

By Michael Fitzhugh
Staff Writer

Monday, March 20, 2017

Adding the investigational advanced breast cancer candidate, abemaciclib, to the already-approved drug fulvestrant, reduced the risk of disease worsening or death for women with HER2-negative disease more than adding a placebo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription